Marleen A. Simmelink-Koel

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics.

Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics.

Journal: JAMA network open

Published: August 13, 2026

Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ+ and Aβ- dementia with Lewy bodies patients.

Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ+ and Aβ- dementia with Lewy bodies patients.

Journal: Alzheimer's research & therapy

Published: February 05, 2026

Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.

Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.

Journal: Alzheimer's research & therapy

Published: August 15, 2025

Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].

Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].

Journal: The journal of prevention of Alzheimer's disease

Published: June 06, 2025

Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?

Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: April 11, 2025

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.

Journal: The journal of prevention of Alzheimer's disease

Published: November 26, 2024

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.

Journal: Nature communications

Published: July 12, 2024

Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.

Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.

Journal: Annals of neurology

Published: June 21, 2024

C1q is increased in cerebrospinal fluid-derived extracellular vesicles in Alzheimer's disease: A multi-cohort proteomics and immuno-assay validation study.

C1q is increased in cerebrospinal fluid-derived extracellular vesicles in Alzheimer's disease: A multi-cohort proteomics and immuno-assay validation study.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: October 21, 2022

Long-term tactile hypersensitivity after nerve crush injury in mice is characterized by the persistence of intact sensory axons.

Long-term tactile hypersensitivity after nerve crush injury in mice is characterized by the persistence of intact sensory axons.

Journal: Pain

Published: October 17, 2022

Plasma proteome profiling identifies changes associated to AD but not to FTD.

Plasma proteome profiling identifies changes associated to AD but not to FTD.

Journal: Acta neuropathologica communications

Published: October 04, 2022

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: July 21, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026